Paper Details

  1. Home
  2. Paper Details

Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study.

Author: AelionJacob A, CoddingChristine E, DokoupilovaEva, DurezPatrick, GenoveseMark C, HugotSophie, IkawaTakashi, KellnerHerbert, LeeSang-Heon, MazurovVadim, MpofuShephard, RichardsHanno B, SupronikJerzy

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Secukinumab did not achieve the primary efficacy endpoint of ACR20 response at week 16 but showed clinically relevant decreases in disease activity score and CRP levels compared to placebo.
Paper Details　
Original Abstract of the Article :
OBJECTIVE: To assess the safety and efficacy of secukinumab, a fully human monoclonal anti-interleukin-17A antibody, in patients with rheumatoid arthritis (RA). METHODS: Patients (n=237) with inadequate response to methotrexate were randomly assigned to receive monthly subcutaneous injections of se...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1136/annrheumdis-2012-201601

データ提供：米国国立医学図書館（NLM）

Secukinumab: A Camel's Journey to Rheumatoid Arthritis Relief

The [autoimmune disease] of [rheumatoid arthritis] can cause significant pain and disability. This study, like a camel seeking a cure for a persistent ailment, explores the potential of [secukinumab] as a treatment for [rheumatoid arthritis]. The researchers, like skilled healers testing a new remedy, conducted a [phase II, dose-finding, double-blind, randomised, placebo controlled study] to evaluate the safety and efficacy of [secukinumab] in patients with [rheumatoid arthritis].

Secukinumab: A Potential Oasis for Rheumatoid Arthritis

The study showed that [secukinumab] had a promising safety profile, but did not reach the primary endpoint of [ACR20 response] at [week 16]. However, it did show significant improvements in [DAS28-CRP] and [high sensitivity CRP levels] at [week 16]. These findings suggest that [secukinumab] may be an effective treatment for [rheumatoid arthritis], but further research is needed to determine the optimal dose and long-term effects.

A Camel's Perspective on Rheumatoid Arthritis

As a camel, I know that pain and stiffness can be debilitating. This study provides hope for individuals suffering from [rheumatoid arthritis], but it also highlights the need for continued research to develop safe and effective treatments.

Dr. Camel's Conclusion

This study offers a glimpse into the potential of [secukinumab] for treating [rheumatoid arthritis]. While further research is needed to confirm its efficacy and optimal dose, this promising treatment offers hope for individuals seeking relief from this debilitating condition. As a researcher, I'm inspired by the ongoing efforts to find solutions for the challenges faced by those with [rheumatoid arthritis].

Date :
  1. Date Completed 2013-07-12
  2. Date Revised 2019-12-10
Further Info :

Pubmed ID

22730366

DOI: Digital Object Identifier

10.1136/annrheumdis-2012-201601

Related Literature

Article Analysis
・Effects of secukinumab injection
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.